Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate

NCT04930965 | Completed Results

• 2 other identifiers: 2020-1600OT2 HL158260
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to assess the effectiveness of the HALT COVID Ambassador educational outreach program on increasing likelihood to vaccinate against COVID-19

Conditions

Covid19; Vaccine Refusal

Keywords

Community Health Worker

Outcome Measures

Primary Outcomes (1)

• Difference in Proportion of Participants "Likely to Vaccinate" Between Study Arms at Month 1

  Vaccine likelihood will be measured using a single question adapted from the CEAL Common Survey (i.e., "On a scale from 1 to 7, with 1 being 'not at all likely' and 7 being 'very likely', how likely are you to get a COVID-19 vaccine in the next month?"), with "likely to vaccinate" defined as a score of 5-7.

  Month 1 follow-up

Secondary Outcomes (3)

• Difference in Proportion of Participants "Likely to Vaccinate" Between Study Arms at Month 2

  Month 2 follow-up

• Difference in Proportion of Participants Who Have Received >=1 Dose of Vaccine Between Study Arms at Month 1

  Month 1 follow-up

• Difference in Proportion of Participants Who Have Received >=1 Dose of Vaccine Between Study Arms at Month 2

  Month 2 follow-up

Study Arms (2)

Intervention

EXPERIMENTAL

Behavioral: Community health worker engagement

Usual care

NO INTERVENTION

Interventions

Community health worker engagement BEHAVIORAL

3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Unlikely to vaccinate in next month
• Age \>=18 years
• Self-identification as Black or African American
• Ability to understand and speak English
• Willingness to engage with HALT COVID Ambassador via in-person or virtual sessions exploring questions and concerns about vaccines

You may not qualify if:

• Unable or unwilling to give informed consent

Sponsors & Collaborators

• Tulane University: lead
• National Institutes of Health (NIH): collaborator

Study Sites (1)

Tulane University Medical Center

New Orleans, Louisiana, 70112, United States

Location

MeSH Terms

Conditions

COVID-19; Vaccination Refusal

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Treatment Refusal; Treatment Adherence and Compliance; Health Behavior; Behavior

Results Point of Contact

• Title: Erin Peacock
• Organization: Tulane University

epeacoc@tulane.edu

504-988-1075

Study Officials

• Marie Krousel-Wood, MD, MSPH

  Tulane University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2021
• First Posted: June 18, 2021
• Study Start: October 5, 2021
• Primary Completion: December 31, 2022
• Study Completion: February 28, 2023
• Last Updated: January 18, 2024
• Results First Posted: January 18, 2024

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)